• Explore /
  • Poster
  • / Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Anthony B. El-Khoueiry

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA

Anthony B. El-Khoueiry , Richard D. Kim , William P. Harris , Max W. Sung , Dirk Waldschmidt , Syma Iqbal , Xiaojing (Amily) Zhang , Keiko Nakajima , Peter R. Galle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Translational Research

Clinical Trial Registration Number

NCT03347292

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 564)

Abstract #

564

Poster Bd #

E3

Abstract Disclosures

Similar Posters

First Author: Richard D. Kim

First Author: Anthony B. El-Khoueiry

First Author: Jaekyung Cheon

First Author: Jamie Grossman